- Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ reviewIf approved, Dyne Therapeutics’ zeleciment rostudirsen could “capture the majority” of the exon-51 Duchenne muscular dystrophy market, given its better efficacy and dosing profile versus Sarepta Th…BioSpace · 4d ago↗ source
- STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’Novo Nordisk sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.STAT · 4d ago↗ source
- A renewed push from the right against abortion pillsThe latest on cyclospora, THC sodas at the grocery store, and more health news from Morning Rounds